Skip to main content

Month: May 2021

BOS Reports First Quarter of the Year 2021 Financial Results

Third Consecutive Profitable Quarter RISHON LE ZION, Israel, May 27, 2021 (GLOBE NEWSWIRE) — BOS Better Online Solutions Ltd. (“BOS” or the “Company”) (NASDAQ: BOSC) reported its financial results for the first quarter of the year 2021. Revenues for the first quarter of 2021 were $7.3 million compared to $7.5 million in the comparable quarter last year. The decrease in revenues was attributed mostly to the RFID division, and reflects the adverse effects of the COVID-19 pandemic. We expect to make up the shortfall in first-quarter revenues during the rest of 2021. Operating profit for the first quarter increased to $234,000 compared to $110,000 in the comparable quarter last year. The increase is attributed to the improvement in the Robotics division operational results (see segment tables below). Financial...

Continue reading

omniQ Receives Purchase Order to Deploy its AI Based Cloud Solution for Georgia State University from ASPIS Parking

omniQ to deploy PERCS™️ (Permitting, Enforcement, Revenue and Collection) Cloud-hosted Solution at Georgia State University in Atlanta, GA PERCS™ represents a Recurring revenue business model Follows growing demand for Company’s AI based solutions from other universities and education institutes, homeland security authorities and various gated communities.SALT LAKE CITY, May 27, 2021 (GLOBE NEWSWIRE) — omniQ Corp (OTCQB: OMQS) (“OMNIQ” or “the Company”), a provider of Artificial Intelligence and Supply Chain (AI)-based solutions, announced today the receipt of a Software as a Service recurring revenue agreement from ASPIS Parking to deploy its PERCS (Permitting, Enforcement, Revenue and Collection) Cloud-hosted Software for Georgia State University. The agreement also includes deployment of multiple omniQ’s eCite Pro™ enforcement...

Continue reading

AIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen

Announces plans to conduct Phase 1/2 clinical study incorporating new inhalation technology if the preliminary results of the testing are positive OCALA, Fla., May 27, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a two-year extension of its Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited (Smoore), a subsidiary of Smoore International Holdings Limited (HKEX: 6969), with the goal of developing Ampligen as a potential inhalation therapy for COVID-19 and potentially other respiratory viral diseases. AIM entered into the agreement on April 1, 2020, to study the utilization of an innovative Smoore inhalation delivery device and Ampligen as a potential treatment approach for the SARS-CoV-2 pandemic. On parallel paths, over the past year, Smoore...

Continue reading

An installation made of Suominen’s nonwoven is on display at Glasshouse Helsinki

Geo PilviThe main material used in the installation is 100% cellulosic and responsibly produced nonwoven by Suominen.Geo Pilvi installationThe installation is called Geo Pilvi and consists of eight folded structures that hang from the ceiling of Glasshouse Helsinki.Megan McGlynnArtist and experimental designer Megan McGlynnSuominen Corporation’s press release on May 27, 2021 at 4:00 p.m. (EEST) An installation by an artist and experimental designer Megan McGlynn is set on display in Glasshouse Helsinki, a retail environment that opened its doors to visitors today in the center of Helsinki. The main material of the installation is from Suominen’s sustainable product portfolio: a biodegradable nonwoven made of cellulosic fibers. The installation is called Geo Pilvi and consists of eight...

Continue reading

Renowned Psychedelic Researcher, James Fadiman, PhD, Joins Wesana Health Scientific Advisory Board

TORONTO and CHICAGO, May 27, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA), an emerging data driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, today announced the addition of renowned psychedelics researcher, psychologist, and writer, James Fadiman, PhD, to its Scientific Advisory Board. In this role, Dr. Fadiman will provide strategic guidance and direction to Wesana’s scientific research efforts related to psychedelic-assisted psychotherapy to treat traumatic brain injury (TBI). Called “America’s wisest and most respected authority on psychedelics and their use” Dr. Fadiman is a pioneer of psychedelics research who...

Continue reading

ScottsMiracle-Gro Announces its Support Regarding Bayer’s Announcement on Potential Changes for Roundup™ in the Consumer Market

MARYSVILLE, Ohio, May 27, 2021 (GLOBE NEWSWIRE) — The Scotts Miracle-Gro Company (NYSE: SMG) said today it welcomes the opportunity to work with Bayer regarding the future of glyphosate-containing Roundup™ products in order to ensure the brand’s future in the consumer marketplace. “We are glad to hear Bayer’s strong public commitment to the consumer market and Roundup’s continued place in it,” said Jim Hagedorn, chairman and chief executive officer of ScottsMiracle-Gro. “Roundup is an iconic brand in the lawn and garden industry and has been trusted by consumers for decades. We are confident there are several options, including the use of effective alternative active ingredients, to ensure that remains the case while continuing to meet the needs of homeowners and retailers.” Hagedorn emphasized that ScottsMiracle-Gro remains committed...

Continue reading

Equifax Canada data indicates COVID-19 financial crisis is not over for consumers, small businesses

Analysis indicates growing concern for uneven K-shaped recoveryAverage Spend on Credit CardsThe line graph charts the average spend on credit cards, which is returning to normal levels.Moving into DelinquencyThe bar graph indicates that credit conditions are improving across age groups.TORONTO, May 27, 2021 (GLOBE NEWSWIRE) — Equifax Canada has released new data indicating that COVID-19 has had a varying impact on consumers and businesses. Many are hurting financially, whereas others have seen improvements to their financial standing. On average consumers have seen their credit card balances decline during the pandemic and the lower debt levels have combined with fewer missed payments to generally boost credit scores. For businesses, however, decreased demand for credit presents a red flag most...

Continue reading

Prestige Announces Agreement to Expand Eye Care Offering with Acquisition of TheraTears

Acquisition adds TheraTears brand to Company’s leading eye care portfolio Acquisition expected to add approximately $60 and $20 million of Revenue and EBITDA, respectively on an annual basis Transaction expected to close during fiscal 2QTARRYTOWN, N.Y., May 27, 2021 (GLOBE NEWSWIRE) — Prestige Consumer Healthcare Inc. (“Prestige” or the “Company”) (NYSE:PBH) today announced that it has entered into a definitive agreement to acquire a portfolio of over-the-counter consumer brands from specialty pharmaceutical company Akorn Operating Company LLC (“Akorn”) for $230 million in cash. The agreement is structured as an asset purchase that delivers anticipated tax benefits of ~$30 million and expected annual EBITDA of ~$20 million equating to a transaction valued at less than 10x pro-forma EBITDA. The transaction is estimated to add...

Continue reading

EnWave Announces 2021 Second Quarter Consolidated Interim Financial Results

VANCOUVER, British Columbia, May 27, 2021 (GLOBE NEWSWIRE) — EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) today reports the Company’s consolidated interim financial results for the second quarter ended March 31, 2021. Consolidated Financial Performance:($ ‘000s) Three months ended March 31,   Six months ended March 31,    2021     2020   Change%     2021     2020   Change%               Revenues   4,686     7,492   (37 %)     12,219     16,101   (24 %)Direct costs   4,208     5,629   (25 %)     10,043     11,042   (9 %)Gross margin   478     1,863   (74 %)     2,176     5,059   (57 %)               Operating expenses              General and administration   1,214     1,558   (22 %)     2,340     3,316   (29 %)Sales and marketing   1,304     1,796   (27 %)     2,825     3,739   (24 %)Research...

Continue reading

Ress Life Investments A/S Half-Year Report – 1 October 2020 – 31 March 2021

   Corporate Announcement no. 17/2021: Half-Year Report 1 October 2020 – 31 March 2021Copenhagen, 27 May 2021 The Board of Directors and the Management have today discussed and approved the Half-Year Report of Ress Life Investments A/S for the period 1 October 2020 – 31 March 2021:Ress Life Investments A/S realised a net profit before and after tax of USD 2,961,937 for the period 1 October 2020 – 31 March 2021. The net profit for the period corresponds to a net return on equity of 1.16%, earnings per share at 26.22 and an increase in net asset value of USD 28.16 per share. The profit before tax mainly relates to positive fair value adjustments offset by administrative expenses and staff costs. The fair value of the Company’s investment assets increased from USD 192,449,408 at 30 September 2020 to USD 205,300,997 at 31 March 2021. Equity...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.